Boston Scientific Corporation (BSX, Financial) has revealed a significant leadership change as Dan Brennan, the company's executive vice president and chief financial officer, plans to retire after nearly three decades of distinguished service. The transition will see Brennan stepping down from his CFO role by the end of June, but he will continue to contribute as a senior advisor to the company until early October.
Jon Monson, currently serving as the senior vice president of investor relations at Boston Scientific, will take over the reins as executive vice president and CFO, effective June 30. This change marks a new chapter for the company as it continues to navigate its strategic financial endeavors under new leadership.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 30 analysts, the average target price for Boston Scientific Corp (BSX, Financial) is $116.34 with a high estimate of $130.00 and a low estimate of $84.11. The average target implies an upside of 22.40% from the current price of $95.05. More detailed estimate data can be found on the Boston Scientific Corp (BSX) Forecast page.
Based on the consensus recommendation from 34 brokerage firms, Boston Scientific Corp's (BSX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Boston Scientific Corp (BSX, Financial) in one year is $76.94, suggesting a downside of 19.05% from the current price of $95.05. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Boston Scientific Corp (BSX) Summary page.
